Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vascular Biogenics Ltd. (VBLT : NSDQ)

• Company Description    Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. Number of Employees: 41

• Price / Volume Information    Yesterday's Closing Price: $1.55 Daily Weekly Monthly 20 Day Moving Average: 281,623 shares Shares Outstanding: 69.33 (millions) Market Capitalization: $107.46 (millions) Beta: 1.09 52 Week High: $3.04 52 Week Low: $1.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.44% 18.76% 12 Week 14.81% 26.23% Year To Date -21.32% -3.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8 HASATAT STREET - MODI`IN ,L3 7178106 ISR ph: 972-8993-5000 fax: 972-8993-5001 ir@vblrx.com http://www.vblrx.com

• General Corporate Information    Officers Dror Harats - Chief Executive Officer Marc Kozin - Chairman Sam Backenroth - Chief Financial Officer Matt Trudeau - Chief Commercial Officer Ruth Alon - Director Peer Information Vascular Biogenics Ltd. (CORR.) Vascular Biogenics Ltd. (RSPI) Vascular Biogenics Ltd. (CGXP) Vascular Biogenics Ltd. (BGEN) Vascular Biogenics Ltd. (GTBP) Vascular Biogenics Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M96883109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 69.33 Most Recent Split Date: (:1) Beta: 1.09 Market Capitalization: $107.46 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.51 Price/Cash Flow: - Price / Sales: 154.39 EPS Growth vs. Year Ago Period: -8.33% vs. Previous Quarter: -8.33% Sales Growth vs. Year Ago Period: -38.92% vs. Previous Quarter: -42.35% ROE 03/31/22 - -69.21 12/31/21 - -63.08 09/30/21 - -66.02 ROA 03/31/22 - -54.63 12/31/21 - -49.82 09/30/21 - -51.68 Current Ratio 03/31/22 - 4.21 12/31/21 - 5.53 09/30/21 - 6.75 Quick Ratio 03/31/22 - - 12/31/21 - 5.53 09/30/21 - 6.75 Operating Margin 03/31/22 - -4,894.40 12/31/21 - -3,895.83 09/30/21 - -3,612.61 Net Margin 03/31/22 - -4,894.40 12/31/21 - -3,895.83 09/30/21 - -3,612.61 Pre-Tax Margin 03/31/22 - -3,703.30 12/31/21 - -3,895.83 09/30/21 - -3,613.39 Book Value 03/31/22 - 0.62 12/31/21 - 0.73 09/30/21 - 0.79 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©